Explicit inclusion of treatment in prognostic modelling was recommended in observational and randomised settings by Riley, RD
Accepted Manuscript
Explicit inclusion of treatment in prognostic modelling was recommended in
observational and randomised settings
R.H.H. Groenwold, K.G.M. Moons, R. Pajouheshnia, D.G. Altman, G.S. Collins,
T.P.A. Debray, J.B. Reitsma, R.D. Riley, L.M. Peelen
PII: S0895-4356(16)30030-0
DOI: 10.1016/j.jclinepi.2016.03.017
Reference: JCE 9145
To appear in: Journal of Clinical Epidemiology
Received Date: 15 September 2015
Revised Date: 1 March 2016
Accepted Date: 23 March 2016
Please cite this article as: Groenwold RHH, Moons KGM, Pajouheshnia R, Altman DG, Collins GS,
Debray TPA, Reitsma JB, Riley RD, Peelen LM, Explicit inclusion of treatment in prognostic modelling
was recommended in observational and randomised settings, Journal of Clinical Epidemiology (2016),
doi: 10.1016/j.jclinepi.2016.03.017.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
Explicit inclusion of treatment in prognostic modelling was recommended in observational 
and randomised settings 
 
 
R.H.H. Groenwold1, K.G.M. Moons1,2, R. Pajouheshnia1, D.G. Altman3, G. S. Collins3, 
T.P.A. Debray1,2, J.B. Reitsma1,2, R.D. Riley4, L.M. Peelen1 
 
1. Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, 
the Netherlands 
2. Dutch Cochrane Center, University Medical Center Utrecht, the Netherlands 
3. Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology 
and Musculoskeletal Sciences, University of Oxford, Oxford, OX3 7LD, United 
Kingdom. 
4. Research Institute for Primary Care and Health Sciences, Keele University, Staffordshire, 
UK, ST5 5BG 
 
 
 
Corresponding author: 
R.H.H. Groenwold, MD, PhD 
Julius Center for Health Sciences and Primary Care 
University Medical Center Utrecht 
PO Box 85500, 3508 GA Utrecht, the Netherlands 
T: +31 88 755 9365; F: +31 88 756 8099; E: r.h.h.groenwold@umcutrecht.nl 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
Funding 
Rolf H.H. Groenwold was funded by the Netherlands Organization for Scientific Research 
(NWO-Veni project 916.13.028). Karel G.M. Moons receives funding from the Netherlands 
Organisation for Scientific Research (project 9120.8004 and 918.10.615). Richard Riley and 
Doug Altman receive funding from an MRC Partnership Grant for the PROGnosis RESearch 
Strategy (PROGRESS) group (grant reference number: G0902393). Gary S. Collins receives 
funding from the Medical Research Council (grant number G1100513). The study sponsors 
had no role in the design of the study, the collection, analysis or interpretation of data, the 
writing of the report or the decision to submit the article for publication. 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4 
 
What is new 
• When developing a prognostic model (that aims to produce accurate probabilities of the 
outcome in case the patient is not treated) using data from a randomised trial in which 
individuals from one arm do not receive treatment, restricting the analysis to untreated 
individuals may be a suitable strategy. However, removing all patients in the treatment 
group will reduce the sample size, leading to greater uncertainty around predictions and 
also to prognostic models that are more prone to overfitting. 
• When developing a prognostic model using data from observational studies with treated 
patients, restricting the analysis to untreated individuals is not appropriate if treatment 
status depends on patient characteristics, including the predictors of the developed model.  
• For either randomised or observational studies, it is preferable to explicitly model 
treatment when developing a prognostic model.  
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ABSTRACT 
Objective: To compare different methods to handle treatment when developing a prognostic 
model that aims to produce accurate probabilities of the outcome of individuals if left 
untreated.  
Study Design and Setting: Simulations were performed based on two normally distributed 
predictors, a binary outcome, and a binary treatment, mimicking a randomised trial or an 
observational study. Comparison was made between simply ignoring treatment (SIT), 
restricting the analytical dataset to untreated individuals (AUT), inverse probability weighting 
(IPW), and explicit modelling of treatment (MT). Methods were compared in terms of 
predictive performance of the model and the proportion of incorrect treatment decisions.  
Results: Omitting a genuine predictor of the outcome from the prognostic model decreased 
model performance, in both an observational study and a randomised trial. In randomised 
trials, the proportion of incorrect treatment decisions was smaller when applying AUT or MT, 
compared to SIT and IPW. In observational studies, MT was superior to all other methods 
regarding the proportion of incorrect treatment decisions.  
Conclusion: If a prognostic model aims to produce correct probabilities of the outcome in the 
absence of treatment, ignoring treatments that affect that outcome can lead to suboptimal 
model performance and incorrect treatment decisions. Explicitly modeling treatment is 
recommended.  
 
Key words: Prognosis; Models, statistical; Computer simulation; Decision support techniques 
Running title: Handling treatment in prognostic modelling 
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1. Introduction 
Prognostic models (or risk scores) are increasingly important for clinical decision making.1,2 
For example, the predicted probability of an outcome, obtained through a prognostic model, 
may serve as the starting point for considerations of treatment initiation: high risks may lead 
to starting treatment, whereas in the case of low risks treatments may be withheld or delayed. 
For example, in the guideline of the European Society of Cardiology,3 it is mentioned that "at 
risk levels >10%, drug treatment is more frequently required", although the authors caution 
that "no threshold is universally applicable". To guide individual treatment decisions, 
prognostic outcome predictions should ideally reflect the predicted course or outcome risk of 
disease if a patient were to remain untreated.2,4  
 
Prognostic models are often developed using data from a randomised trial or an observational 
study, in which (at least part of the) individuals are treated.5 If treatments are effective in 
reducing the risk of the predicted outcomes, simply ignoring those treatments in the 
development of a prognostic model may result in incorrect predictor-outcome associations 
and hence incorrect risk predictions of the natural history when used in new individuals.6 
Even though predictions are correct for those among whom the model was developed (the 
‘derivation set’), they  may not generalize to future individuals who may be treated 
differently. In other words there is a danger of risk predictions being confounded by 
treatment: risk predictions appear low because of treatment, but in future patients the true risk 
might be substantially higher if they remain untreated. Further complications arise when 
treatment decisions in the data available were already being based on the values of the 
predictors in the model. For example, in patients with hypertension the observed predictive 
effect of blood pressure for cardiovascular outcomes is likely to be diluted, as those with high 
blood pressure will receive anti-hypertensive treatment, based on the observed high blood 
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pressure, in turn lowering their predicted risk. Thus if a prognostic model is developed using 
these data, the effect of blood pressure is likely to be downwardly biased and therefore risk 
predictions may be too low in future untreated individuals. 
 
Methods to account for treatments in the development of a prognostic model to be used for 
predicting the health course of individuals in the absence of treatment include simply ignoring 
treatment,5 restricting the development set to untreated individuals,6 censoring observations 
after treatment has started,7 and explicit modeling of the treatment.8 Also, in the TRIPOD 
statement, there is an item on the reporting of treatment received among participants of a 
study developing or validating a multivariable prediction model for diagnosis or prognosis.9 
 
In this article, we evaluate these different methods in situations that aim to develop a 
prognostic model generating  predictions in case individuals were to remain untreated, which 
serve as input for treatment decisions. In particular, we examine how the methods impact 
upon the predictive performance and proportion of correct indications of treatment of a 
prognostic model being developed using data from a randomised or observational study.  
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2. Consequences of ignoring treatment in different phases of model development 
The development and introduction of a new prognostic model comprises four distinct phases: 
derivation, validation, impact assessment, and implementation of the model.1 As indicated 
above, for a model to be used to guide treatment decisions, the predictions made by the model 
should be the outcome risks of individuals if no treatment were to be given. This implies that 
such models should be developed in untreated populations. Nevertheless, in all phases of 
prognostic modelling research, some portion of the study population may actually be treated 
by an effective treatment.  
 
When deriving a model in a treatment naïve population, the model will indeed provide risk 
predictions that reflect what will happen if a future but similar individual remains untreated. 
However, when part of the population is treated and treatment is ignored in the model 
derivation phase, the risk predictions from the model will be too low when validated or 
applied in individuals who are yet untreated. To what extent the predictions will be too low 
likely depends on the proportion of treated individuals in the derivation set and the magnitude 
of the treatment effect. Figure 1 illustrates this impact of ignoring treatment in the 
development of a prognostic model. 
 
The impact of ignoring treatment when validating the developed model in new individuals 
obviously depends on what cohort of patients have been used in the derivation phase. If the 
model was derived in a treatment naïve population, the model will provide correct predictions 
if the individuals in the validation set are all untreated too; the predicted risks will correspond 
reasonably well with the observed risks. However, if such a developed model is validated in a 
(partly) treated population, the predicted risks will appear to be too high, if treatment is 
simply ignored in the validation phase.  
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When a model is derived in a (partly) treated population and this treatment is ignored in the 
development, the predicted risk will be too low, when validating the model in a treatment 
naïve population. If the proportion of treated individuals and the reasons for treatment are the 
same in the derivation and the validation phase, however, the predicted risks will appear to be 
correct in the validation phase, while in fact both are too low in those who are treated, if these 
risks are considered the outcome risks if no treatment were to be given.  
 
How treatment was handled in the derivation and validation phase of model development 
directly impacts the usefulness of a prognostic model in daily clinical care, because incorrect 
predicted risks may lead to incorrect treatment decisions (e.g., in the presence of a risk 
threshold above which treatment is administered). When predicted risks are too high, too 
many individuals may receive treatment, while predicted risks that are too low risk may lead 
to undertreatment.  
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3. Methods 
3.1 Outline of simulations 
In this section, we focus on different methods to handle treatment in the derivation of a 
prognostic model and their possible impact in terms of incorrect treatment decisions. The 
simulated scenarios are outlined in Figure 2. In all scenarios, there are two (possibly 
correlated) variables (denoted X1 and X2), which are associated with the outcome of interest 
(Y). Each of these variables can be considered as a single predictor, or as a summary of 
multiple predictors (i.e., X1 and X2 are variables or vectors of variables). In addition, there is a 
single binary treatment (T). Half of the chosen scenarios mimic data from a randomised trial, 
in which treatment was a random process (i.e., independent of the variables X1 and X2), and 
the remaining scenarios are chosen to mimic observational data, in which treatment decisions 
were based on the values of the variables X1 and X2. We assume that this treatment is 
effective in reducing the outcome. We also assume that there are no other sources of bias, 
apart from the potential confounding effect by X1 and X2. 
 
3.2 Simulation setup 
All simulations and analyses were performed in R for windows, version 3.1.3.10 The 
simulation code is available upon request.  
 
Simulated datasets of 1000 individuals were generated. Each dataset consisted of four 
variables: two continuous, standard normally distributed variables (indicated by X1 and X2), a 
binary treatment (indicated by T), and a binary outcome (indicated by Y). Data were 
generated by first sampling X1 and X2 from a multivariate normal distribution with a 
correlation of 0 or 0.3 between the two variables, which is a realistic range of correlations 
typically observed in behavioural, socioeconomic, and physiological factors in biomedical 
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research.11 Next, the binary treatment status and outcome were sequentially generated by 
sampling from a Bernoulli distribution with individual-specific probabilities of treatment and 
outcome status, π =pi,t and π= pi,y, respectively. The true individual-specific probabilities of 
treatment status (pi,t) (i.e., the probability of receiving treatment) were generated using the 
logistic model: 
logit(pi,t) = α0 + α1X1i + α2X2i ,  (1) 
 
which implies that treatment decisions are based on the variables X1 and X2. The true 
individual-specific probabilities of outcome status (pi,y) were generated using the logistic 
model: 
logit(pi,y) = β0 + β1Ti + β2X1i + β3X2i , (2) 
 
which implies that the probability of the outcome depends on the variables X1 and X2 as well 
as treatment status (T). The values of the parameters α0, α1, α2, β0, β1, and β2 (Figure 2) 
differed between scenarios (see Section 3.3). Notably, in those scenarios that mimicked a 
randomised trial, the parameters α1 and α2 were set to zero, in order to make treatment 
allocation a random process. A step-by-step guide to the simulation study is now outlined. 
 
3.3 Step 1: Choose one of 10 simulated scenarios 
To assess the impact of different methods to handle treatment in the development of a 
prognostic model, 10 different scenarios were considered and, in each of these, data were 
generated using the set-up described in Section 3.2. The different scenarios and parameter 
settings are summarized in Table A1 (in the Appendix). 
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Scenarios 1-5 represent the development of a prognostic model using data from a randomised 
trial. In scenario 1 (default scenario), the variables X1 and X2 were considered independent 
(ρ=0). Both variables were equally associated with the outcome: both increased the log(odds) 
of the outcome by 1 per unit increase (i.e., β1=β2= 1). Treatment assignment was a random 
process (α1=α2=0) and treatment was present in approximately 50% of the individuals. 
Treatment was considered to be effective in preventing the outcome (OR=0.5). 
Approximately 10% of the individuals experienced the outcome of interest. In scenarios 2-5 
one of the simulation parameters from scenario 1 was changed. In scenario 2, the variables X1 
and X2 were correlated (ρ=0.3). In scenario 3, the association between X1 and the outcome 
was doubled (β1=2), while the association between X2 and the outcome remained unchanged 
(β2=1). This resembles a situation in which one of two (sets of) variables has a larger 
contribution in predicting the outcome. In a similar way, in scenario 4, the association 
between X2 and the outcome was doubled (and thus twice as large as the association between 
X1 and the outcome). In scenario 5, the treatment was less effective (OR=0.9).  
 
Scenarios 6-10 were the same as scenarios 1-5, respectively, except that now treatment 
assignment was not a random process, but depended on X1 and X2, thus mimicking the 
development of a prognostic model using data from an observational study in which some 
patients received treatment. Both X1 and X2 increased the log(odds) of the treatment by 1 per 
unit increase (i.e., α1=α2= 1).  
 
3.4 Step 2: Implement the different methods to develop prognostic models in the 
presence of treatments 
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In each simulated dataset, eight different approaches were applied to develop a prognostic 
model to predict outcome Y. The eight different methods are summarized in Table A2 (in the 
Appendix) and described hereafter. 
 
For all methods, the model relating the outcome to the predictors was a logistic regression 
model (in line with the data generating model). For half of the methods both predictors (i.e. 
X1 and X2) were considered observed, whereas for the other half the predictor X2 was 
considered unobserved. The latter may also correspond to a situation in which a possible 
predictor of the outcome is intentionally omitted from the model, for example because the 
measurement of the predictor is very costly, or invasive. As previously indicated, each of the 
variables X1 and X2 can be considered as a combination (or reflection) of multiple predictors, 
thus even the models including only X1 could be considered as prognostic models including 
multiple predictors. Each of the methods differed in the way treatment was accounted for.  
 
For methods 1 and 2, which are the simply ignore treatment (SIT) methods, treatment was 
simply ignored: method 1 was a model regressing Y on X1, ignoring X2 and T; method 2 was 
a model regressing Y on X1 and X2, ignoring T.  
 
For methods 3 and 4, analysis of untreated individuals (AUT), analysis was performed using 
information on untreated individuals only (i.e., restriction to those for whom T=0); the 
outcome models were the same as in methods 1 and 2.  
 
Methods 5 and 6 were based on inverse probability weighting (IPW). First, a logistic 
regression model was fitted regressing treatment (T) on the predictor X1 (method 5), or 
regressing T on the predictors X1 and X2 (method 6). This yielded individual probabilities of 
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being treated for all individuals in the dataset. Next, treated individuals were weighted by the 
inverse of the probability of being treated, while untreated individuals were weighted by the 
inverse of the probability of not being treated. Weighting thus created a pseudo-population in 
which treatment status was independent of the predictors X1, or X1 and X2. A weighted 
regression model was then fitted regressing Y on X1 (method 5), or regressing Y on X1 and X2 
(method 6).  
 
In methods 7 and 8, treatment was explicitly modelled as a separate predictor (MT): method 7 
was a model regressing Y on X1 and T, ignoring X2; method 8 was a model regressing Y on 
X1, X2, and T. None of the methods included corrections for optimism, as no selection 
procedure was used to select predictors for inclusion in the final model.12  
 
3.5 Step 3: Calculate and compare parameters of apparent performance of the 
developed models 
For each scenario, 1000 datasets of 1000 individuals each were created, and the prognostic 
models were developed and evaluated for each dataset. The values of the performance 
measures were then averaged across all 1000 datasets. For each scenario separately, the 
apparent performance of the different methods to handle treatment in the development of a 
prognostic model was compared using the Brier score,13 Harrell's c-statistic,14 the observed by 
expected risk prediction ratio, the standard errors of the association between the predictor X1 
and the outcome, and the proportion of incorrect treatment decisions. These performance 
measures were also compared against their optimal value, which was calculated based on the 
data generating model (model 2 in Section 3.2). For each individual, the untreated probability 
of the outcome could be calculated based on their  values of the variables X1, X2, while setting 
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treatment status to untreated (T=0). This model-based untreated probability of the outcome 
was then used to estimate the optimal values of the different performance measures. 
 
The impact on treatment decisions was assessed by calculating the proportion of false-positive 
treatment decisions (i.e., the proportion of individuals who are treated, while in fact they 
should not be treated) and the proportion of false-negative treatment decisions (i.e., the 
proportion of individuals who are not treated, while in fact they should be treated). For each 
individual, the true probability of the occurrence of the outcome if the individual remained 
untreated was calculated based on the true outcome model. Based on this true untreated 
probability, a correct treatment decision could be made: if the untreated probability of an 
outcome event exceeds an (a-priori chosen) treatment threshold, an individual should be 
treated, while the individual should not be treated if the probability does not exceed the 
threshold. This was compared to the actual treatment decision, which was based on the 
prediction model that was developed with one of the considered methods (described in 
Section 3.4). For the scenarios 1 (randomised trial) and 6 (observational data), the proportions 
of incorrect treatment decisions were estimated for a range of treatment threshold between 
0.025 and 0.5. For all other scenarios, the treatment threshold was set at 10%, i.e., individuals 
receive treatment if their predicted risk exceeds 10%, while they remain untreated if their 
predicted risk is lower than the threshold.  
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4. Results 
4.1 Development of a prognostic model using data from a randomised trial 
Figure 3 shows the impact different methods have on treatment decisions for scenario 1, 
which mimics development of a prognostic model in a randomised study. Since the results for 
the models SIT1, SIT2, MT1, and MT2 were equal to IPW1, IPW2, AUT1, and AUT2, 
respectively, only the results for the first four are plotted. Both panels show that as the 
treatment threshold increases, the probability of a false-positive treatment decision decreases 
and the probability of a false-negative treatment decision increases. The models in which only 
one of the two predictors is included (SIT1 and MT1) are clearly inferior to the models in 
which both predictors are included (SIT2 and MT2). Although the SIT2 model results in fewer 
false-positive treatment decisions than the MT2 model, the latter model results in fewer false-
negative treatment decisions. 
 
In Table 1, the impact different methods have on treatment decisions is shown for all 
scenarios, using a treatment threshold of 10%. Explicitly modelling treatment (MT) and 
analysis of untreated individuals (AUT) led to similar proportions of incorrect treatment 
decisions. Irrespective of the method used, proportions of incorrect treatment decisions (either 
false-positive or false-negative treatment decisions) increase when omitting predictor X2 from 
the model and can be as large as 0.444 (MT1, scenario 4). When modelling both predictors X1 
and X2, yet ignoring treatment (SIT2 or IPW2), the probability of a false-negative treatment 
decision (i.e., not treating an individual when in fact they should be treated) is still 
considerably large. For example, in scenario 1, the probability of a false-negative treatment 
decision is 0.208 for methods SIT2 and IPW2, whereas it is 0.066 and 0.058 for AUT2 and 
MT2, respectively. The reason is that the predicted probabilities of the outcome in the absence 
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of treatment are too low: a probability below the treatment threshold might actually be the 
result of treatment and thus in the absence of treatment, this probability should be higher. 
 
Irrespective of the method used, adding a genuine predictor to the model improves the Brier 
score (smaller values indicate better performance) as well as the c-statistic (larger values 
indicate better performance) (Table 2). Methods in which predictor X2 is considered 
unobserved performed better under scenario 3 than under scenario 4, because in scenario 4 the 
predictor X2 is the most influential predictor, whereas in scenario 3 the most influential 
predictor is X1. Although performance improves when explicitly modelling treatment (MT1 
and MT2), this improvement is small and ignoring treatment (SIT1 and SIT2) appears to have 
relatively little impact. The observed-to-expected ratio was 1.000 for all methods, except for 
the analysis of untreated individuals (AUT), because the treatment was effective and the 
expected probability of the outcome among the untreated is higher than the overall probability 
of the outcome. Restriction to just untreated individuals reduces the sample size, which results 
in larger standard errors compared to the other methods.  
 
4.2 Development of a prognostic model using data from an observational study 
Figure 4 shows the impact different methods have on treatment decisions for scenario 6, 
which mimics development of a prognostic model in observational data. Similar patterns are 
observed as in Figure 3. However, the probability of false-positive treatment decisions is less 
affected by excluding the second predictor from the model. Although analysis of untreated 
individuals (AUT) results in lowest probabilities of false-positive treatment decisions, this 
model is clearly inferior to a model in which treatment is explicitly modelled (MT) when 
comparing probabilities of false-negative treatment decisions.  
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Table 3 shows the impact different methods have on treatment decisions if the prognostic 
model is developed using observational data, using a treatment threshold of 10%. Again, 
including both predictors X1 and X2 improves treatment decisions. Compared to the results of 
simulations mimicking a randomised trial (Table 1), in the simulations of observational data 
the analysis of untreated individuals more often leads to false-negative treatment decisions 
(and less often to false-positive treatment decisions). The reason is that in the simulated 
scenarios on average the untreated individuals have a relatively low probability of the 
outcome, leading to an underestimation of the actual probability of the outcome and, hence, 
an increased probability of a false-negative treatment decision.  
 
The methods SIT, IPW, and MT showed similar performance (Brier score and c-statistic) 
(Table 4). The only exception is the analysis of untreated individuals (AUT), which yields 
Brier scores that are smaller, e.g., the Brier score of the model including treatment: e.g., 0.040 
for AUT2 vs 0.064 for MT2 (scenario 3). The observed-to-expected ratio was larger than 1 for 
the analysis of untreated individuals (AUT), because the simulated scenarios were such that 
particularly high-risk individuals were treated (thus selecting individuals with a relatively low 
probability of the outcome for the analysis of untreated individuals). Again, restriction to 
untreated individuals (AUT) reduces sample size, which results in larger standard errors 
compared to the other methods.  
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5. Discussion 
This simulation study shows that when developing a prognostic model, ignoring an effective 
treatment results in incorrect predictions of the outcome if an individual were to remain 
untreated. To resolve this, in the case of randomised trials one can either restrict analyses to 
untreated individuals, or include all treated and untreated individuals with treatment included 
as a predictor in the model. The latter approach is recommended as the sample size stays 
larger and is thus far more efficient to identify genuine predictor-outcome associations. When 
prognostic models are developed using data from observational studies, analysis of untreated 
individuals only is not appropriate because in observational data, those who are untreated may  
have a relatively high (or low) probability of the outcome, leading to an overestimation (or 
underestimation) of the outcome risk. Including treated as well as untreated individuals and 
including treatment as a predictor in the model will overcome this problem. 
 
Typically, the development of a prognostic model starts with derivation of the model in one 
cohort, followed by validation in another cohort, and finally implementation in clinical 
practice.1,9 Here, we focused on the first step, i.e., derivation of the prognostic model and its 
apparent (internal) performance in the same data used to develop the model. If the model is 
derived in a treatment-naïve population, yet validated in a non-treatment-naïve population (or 
vice versa), the performance of the model may be poor if treatment is ignored at either of the 
two phases. This may partly explain poor performance when applying a prognostic model 
outside the population in which the model was derived.15 Also, importantly, our simulations 
show that developing or validating the model in a subset of untreated individuals may not 
yield optimal performance, if treatment assignment is not a random process (scenarios 6-10). 
In that case, treatment should explicitly be taken in to account when modelling the outcome. 
Notably, when developing a prognostic model using data from an observational study, some 
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confounders of the treatment-outcome relation may be unobserved. The models in which the 
predictor X2 is considered unobserved mimic this situation (i.e., the models SIT1, AUT1, 
IPW1, and MT1). When comparing explicit modelling of treatment (MT1) with ignoring 
treatment (SIT1), in the scenarios considered the former approach is superior in terms of false-
positive treatment decision, Brier score, and c-statistic, while inferior in terms of standard 
error and false-negative treatment decision. The decision to model treatment explicitly should 
therefore  take into account which of the performance measures is considered most important. 
 
For each scenario and for each method considered, we assessed the impact of omitting one 
(set of) predictor(s) for the outcome from the prognostic model (specifically, the predictor X2 
was considered unobserved and thus omitted from the model). Obviously, omitting a 
relatively weak predictor from the model has less impact on the performance of the prognostic 
model than omitting a relatively strong predictor. Likewise, when the treatment has a 
relatively small effect on the outcome compared to the predictors included in the model 
(scenarios 5 and 10), ignoring it probably will have less impact compared to ignoring a 
treatment that has a large effect on the outcome. 
 
A clear advantage of simulation studies, in contrast to using empirical data, is that methods 
can be compared to a reference (in this case the ‘true’ probability of the outcome if an 
individual remains untreated). An obvious downside of simulation studies is that simulated 
scenarios may be deemed unrealistic. For example, we simulated only two continuous 
predictors of the outcome, whereas in prognostic research multiple predictors are likely to be 
considered (including non-continuous ones). However, these two predictors can of course also 
be considered as combinations of multiple predictors, including dichotomous, categorical and 
continuous predictors, and the results of our simulations likely also apply to such settings. 
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Furthermore, only binary outcomes were considered, and time to occurrence of the outcome 
was ignored. In addition, we focused on the development of prognostic models in a setting in 
which treatment was initiated at the start of follow-up for each individual and remained 
constant during follow-up. Interactions between predictors and treatment were not considered 
in the simulated scenarios (i.e., no treatment effect modification). In prognostic studies, in 
which the strength of a prediction changes in case treatment is given, such interactions may be 
required to model the data appropriately.  
 
In the method that applied inverse probability weighting, the treatment was not included as a 
predictor in the (weighted) model regressing the outcome on the predictors. Consequently, the 
method in which treatment was simply ignored (SIT) and the IPW method yielded the same 
results in case of developing the model using data from a randomised trial. The IPW method 
could be improved upon by including the treatment in the weighted outcome model.  
 
Future research could address the possible impact of time-varying treatments in this setting. In 
randomised trials, information on allocated treatment (i.e., intention-to-treat) may be 
insufficient and detailed information on actual use may be required. Also other ‘treatments’ 
such as lifestyle changes (including dietary habits) and non-pharmacological interventions 
such as surgical interventions should be considered. Furthermore, the consequences of the 
choice of method to handle treatments in diagnostic prediction research might be different 
from prognostic research, because for example treatments already may have been started 
based on symptoms of the target condition before the measurements of the diagnostic test(s) 
under evaluation are made. Likewise, in prognostic studies, the treatment may have been 
started before the measurement of the predictor too, and subsequently affect the predictor 
value. These situations were not addressed in this study. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
22 
 
 
Based on the results, several recommendations can be made, which are summarized in the 
Text Box. 
 
We conclude that ignoring treatments that affect the outcome in the development of a 
prognostic model can result in incorrect predicted probabilities for individuals if they were to 
remain untreated, which in turn may lead to incorrect treatment decisions. A solution is to 
explicitly model such treatments in the development of a prognostic model, although this may 
be challenging particularly when treatment status changes over time or when treatment effect 
is modified by patient-level covariates. Regardless, researchers who develop a prognostic 
model must be explicit in how treatment was handled, as recommended in the TRIPOD 
Statement for reporting prediction models,9 and be clear how absolute risk prediction derived 
from a prognostic model should be viewed in the context of current treatment strategies.  
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FIGURES 
 
Figure 1. Impact of ignoring treatment in prognostic modelling research. 
Legend Figure 1 
The top panel shows risk predictions of the outcome made by a prognostic model derived in a 
treatment-naïve population or a population in whom everyone is treated. Treatment is 
assumed to be equally effective on a relative scale in all individuals (constant risk ratio for 
treatment), yet ignored in the development of the prediction model. Hence, the predictions 
based on the model developed in the treated population underestimate the true untreated risk. 
 
The middle panel shows a hypothetical distribution of baseline risk in a population in which 
treatment decision are to be made. In the presence of a treatment threshold, above which 
treatment is initiated, the predicted untreated risks based on the model derived in the 
treatment-naïve population yield correct treatment decisions (shaded grey area). 
 
The bottom panel shows the same hypothetical distribution of baseline risk in a population in 
which again treatment decision are to be made. The predicted untreated risks based on the 
model derived in the treated population are too low and thus for some subjects their predicted 
untreated risk drops below the threshold, leading to incorrectly withholding treatment (i.e., 
undertreatment, false-negative treatment decision). These are indicated by the striped grey 
area. The shaded grey area indicates correct treatment initiation irrespective of the incorrect 
predicted risks. 
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Figure 3. Incorrect treatment decisions based on prognostic models developed using 
data from a randomised trial. 
Legend Figure 3 
Graphs show probability of false positive (left panel) and false negative (right panel) 
treatment decisions when developing a model in the presence of an effective treatment, which 
is differently handled by the different methods. SIT: simply ignore treatment (in SIT1 
predictor X2 is considered unobserved; in SIT2 both predictors X1 and X2 are considered 
observed); MT: model includes treatment (in MT1 predictor X2 is considered unobserved; in 
MT2 both predictors X1 and X2 are considered observed). See text for details. 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
28 
 
Figure 4. Incorrect treatment decisions based on prognostic models developed using 
observational data. 
 
Legend Figure 4 
Graphs show probability of false positive (left panels) and false negative (right panels) 
treatment decisions when developing a model in the presence of an effective treatment, which 
is differently handled by the different methods. SIT: simply ignore treatment (in SIT1 
predictor X2 is considered unobserved; in SIT2 both predictors X1 and X2 are considered 
observed); AUT: analysis of untreated individuals (in AUT1 predictor X2 is considered 
unobserved; in AUT2 both predictors X1 and X2 are considered observed); IPW: inverse 
probability weighting (in IPW1 predictor X2 is considered unobserved; in IPW2 both 
predictors X1 and X2 are considered observed); MT: model includes treatment (in MT1 
predictor X2 is considered unobserved; in MT2 both predictors X1 and X2 are considered 
observed). See text for details.
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Text box. Recommendations on handling treatments in the development of prognostic 
models. 
 If a prognostic model aims to produce accurate individual probabilities of the outcome in 
the absence of treatment, ignoring treatments that affect the outcome in the development 
of such a model can lead to suboptimal model performance, incorrect predicted 
probabilities, and thus suboptimal treatment decisions.  
 Restricting the analysis to untreated individuals may only be a suitable strategy when 
developing a prognostic model using data from a randomised trial in which individuals 
from one treatment arm truly receive no treatment (or placebo), but not in the case of a 
randomised trial that compares two active treatments. Furthermore, restriction to 
untreated individuals reduces the sample size and thus the precision of estimated 
predictor-outcome associations.  
 Restricting the analysis to untreated individuals is not appropriate when prognostic 
models are developed using data from observational studies in which treatment status 
depends on patient characteristics (including the predictors). Instead, it is preferred to 
explicitly model treatments that affect the outcome when developing a prognostic model.  
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TABLES 
 
Table 1. Impact on treatment decisions of methods to develop prognostic models using 
randomised data. 
  Method 
 Sce
nari
o 
SIT1 SIT2 AUT1 AUT2 IPW1 IPW2 MT1 MT2 
Fa
lse
 
po
sit
iv
e 
tr
ea
tm
en
t 
de
ci
sio
n
 
1. 0.172 0.002 0.290 0.038 0.172 0.002 0.286 0.035 
2. 0.132 0.001 0.219 0.033 0.132 0.001 0.217 0.028 
3. 0.082 0.001 0.127 0.021 0.082 0.001 0.126 0.018 
4. 0.318 0.001 0.451 0.023 0.318 0.001 0.444 0.018 
5. 0.214 0.017 0.235 0.035 0.214 0.017 0.234 0.031 
 
Fa
lse
 
n
eg
a
tiv
e 
tr
ea
tm
en
t 
de
ci
sio
n
 
1. 0.346 0.208 0.217 0.066 0.347 0.208 0.220 0.058 
2. 0.293 0.191 0.188 0.061 0.292 0.191 0.189 0.054 
3. 0.240 0.158 0.167 0.059 0.240 0.158 0.167 0.052 
4. 0.384 0.152 0.262 0.052 0.385 0.152 0.266 0.045 
5. 0.286 0.072 0.268 0.074 0.286 0.072 0.268 0.062 
 
Legend Table 1 
Abbreviations: SIT: simply ignore treatment (in SIT1 predictor X2 is considered unobserved; in 
SIT2 both predictors X1 and X2 are considered observed); AUT: analysis of untreated individuals 
(in AUT1 predictor X2 is considered unobserved; in AUT2 both predictors X1 and X2 are 
considered observed); IPW: inverse probability weighting (in IPW1 predictor X2 is considered 
unobserved; in IPW2 both predictors X1 and X2 are considered observed); MT: model includes 
treatment (in MT1 predictor X2 is considered unobserved; in MT2 both predictors X1 and X2 are 
considered observed). 
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Table 2. Performance of methods to develop prognostic models using randomised data. 
  Method  
 Scenario SIT1 SIT2 AUT1 AUT2 IPW1 IPW2 MT1 MT2 Reference 
Br
ie
r 
sc
o
re
 1. 0.082 0.074 0.099 0.087 0.082 0.074 0.081 0.072 0.073 
2. 0.081 0.072 0.096 0.085 0.081 0.072 0.080 0.071 0.072 
3. 0.070 0.061 0.080 0.069 0.070 0.061 0.069 0.060 0.061 
4. 0.088 0.062 0.102 0.070 0.088 0.062 0.087 0.061 0.061 
5. 0.085 0.076 0.088 0.078 0.085 0.076 0.085 0.076 0.076 
 
c-
st
a
tis
tic
 
1. 0.728 0.817 0.726 0.818 0.728 0.817 0.742 0.826 0.824 
2. 0.780 0.843 0.778 0.842 0.780 0.843 0.790 0.851 0.849 
3. 0.860 0.899 0.858 0.898 0.860 0.899 0.866 0.903 0.902 
4. 0.685 0.899 0.682 0.898 0.685 0.899 0.698 0.903 0.902 
5. 0.729 0.818 0.728 0.819 0.729 0.818 0.731 0.820 0.818 
 
O
:E
 
ra
tio
 
1. 1.000 1.000 0.801 0.801 1.000 1.000 1.000 1.000 1.000 
2. 1.000 1.000 0.807 0.807 1.000 1.000 1.000 1.000 1.000 
3. 1.000 1.000 0.838 0.838 1.000 1.000 1.000 1.000 1.000 
4. 1.000 1.000 0.835 0.835 1.000 1.000 1.000 1.000 1.000 
5. 1.000 1.000 0.970 0.970 1.000 1.000 1.000 1.000 1.000 
 
St
a
n
da
rd
 
er
ro
r 
1. 0.121 0.132 0.158    0.175    0.120   0.130   0.122  0.133   
2. 0.130  0.138  0.172   0.184   0.128   0.136   0.131  0.140   
3. 0.164  0.187  0.223  0.257  0.157  0.179  0.167 0.191   
4. 0.113  0.145  0.149  0.196   0.112   0.141  0.114 0.147   
5. 0.119  0.130  0.167   0.184   0.119   0.129   0.120  0.131   
 
 
Legend Table 2 
Abbreviations: SIT: simply ignore treatment (in SIT1 predictor X2 is considered unobserved; in 
SIT2 both predictors X1 and X2 are considered observed); AUT: analysis of untreated individuals 
(in AUT1 predictor X2 is considered unobserved; in AUT2 both predictors X1 and X2 are 
considered observed); IPW: inverse probability weighting (in IPW1 predictor X2 is considered 
unobserved; in IPW2 both predictors X1 and X2 are considered observed); MT: model includes 
treatment (in MT1 predictor X2 is considered unobserved; in MT2 both predictors X1 and X2 are 
considered observed). The O:E ratio is the ratio of the mean observed risk of the outcome and the 
mean predicted risk of the outcome. Ratios are average over 1000 simulations. Standard errors 
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are the average standard error of the association between the predictor X1 and the outcome, 
averaged over 1000 simulations. 
Note that the method in which treatment as well as the predictors X1 and X2 are explicitly 
modelled performs even better than the reference (which is based on the data generating model), 
because chance processes are also accounted for in the analytical method.  
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Table 3. Impact on treatment decisions of methods to develop prognostic models using data 
from an observational study. 
  Method 
 Sce
nar
io 
SIT1 SIT2 AUT1 AUT2 IPW1 IPW2 MT1 MT2 
Fa
ls
e 
po
sit
iv
e 
tr
ea
tm
en
t 
de
ci
sio
n
 
6. 0.172 0.001 0.119 0.029 0.168 0.004 0.143 0.037 
7. 0.111 0.001 0.076 0.023 0.108 0.004 0.100 0.033 
8. 0.074 0.001 0.060 0.017 0.072 0.003 0.064 0.025 
9. 0.328 0.001 0.063 0.016 0.318 0.003 0.095 0.024 
10. 0.201 0.013 0.053 0.023 0.186 0.020 0.070 0.032 
 
Fa
ls
e 
n
eg
a
tiv
e 
tr
ea
tm
en
t 
de
ci
sio
n
 
6. 0.351 0.249 0.500 0.124 0.359 0.204 0.409 0.063 
7. 0.331 0.251 0.484 0.139 0.340 0.200 0.366 0.065 
8. 0.261 0.197 0.295 0.099 0.267 0.155 0.294 0.050 
9. 0.377 0.198 0.843 0.103 0.394 0.153 0.731 0.052 
10. 0.302 0.088 0.663 0.172 0.327 0.101 0.577 0.084 
 
 
Legend Table 3 
Abbreviations: SIT: simply ignore treatment (in SIT1 predictor X2 is considered unobserved; in 
SIT2 both predictors X1 and X2 are considered observed); AUT: analysis of untreated individuals 
(in AUT1 predictor X2 is considered unobserved; in AUT2 both predictors X1 and X2 are 
considered observed); IPW: inverse probability weighting (in IPW1 predictor X2 is considered 
unobserved; in IPW2 both predictors X1 and X2 are considered observed); MT: model includes 
treatment (in MT1 predictor X2 is considered unobserved; in MT2 both predictors X1 and X2 are 
considered observed). 
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Table 4. Performance of methods to develop prognostic models using observational data. 
  Method  
 Scenario SIT1 SIT2 AUT1 AUT2 IPW1 IPW2 MT1 MT2 Reference 
Br
ie
r 
sc
o
re
 6. 0.085 0.078 0.063 0.058 0.085 0.079 0.085 0.077 0.078 
7. 0.079 0.072 0.051 0.048 0.079 0.073 0.078 0.071 0.072 
8. 0.072 0.065 0.045 0.041 0.072 0.066 0.072 0.064 0.064 
9. 0.089 0.065 0.052 0.041 0.090 0.066 0.088 0.064 0.064 
10. 0.083 0.074 0.046 0.043 0.083 0.075 0.082 0.074 0.075 
 
c-
st
a
tis
tic
 
6. 0.708 0.789 0.693 0.792 0.708 0.789 0.711 0.799 0.796 
7. 0.762 0.819 0.739 0.814 0.762 0.818 0.763 0.827 0.825 
8. 0.853 0.886 0.847 0.886 0.853 0.885 0.854 0.890 0.889 
9. 0.671 0.886 0.636 0.886 0.671 0.885 0.696 0.890 0.889 
10. 0.727 0.816 0.695 0.796 0.727 0.814 0.742 0.817 0.815 
 
O
:E
 
ra
tio
 
6. 1.000 1.000 1.435 1.435 1.014 0.899 1.000 1.000 1.000 
7. 1.000 1.000 1.710 1.710 1.017 0.892 1.000 1.000 1.000 
8. 1.000 1.000 1.871 1.871 1.018 0.908 1.000 1.000 1.000 
9. 1.000 1.000 1.888 1.888 1.044 0.906 1.000 1.000 1.000 
10. 1.000 1.000 2.030 2.030 1.058 0.991 1.000 1.000 1.000 
 
St
a
n
da
rd
 
er
ro
r 
6. 0.117  0.125  0.203  0.225  0.117  0.127  0.124  0.137   
7. 0.128  0.135  0.244  0.258   0.129  0.139  0.139  0.147  
8. 0.159  0.176  0.289  0.333  0.154  0.179  0.165  0.192   
9. 0.111  0.138  0.218  0.275  0.111  0.140  0.118  0.152   
10. 0.120  0.131  0.238  0.260  0.120  0.133  0.126  0.140   
 
 
Legend Table 4 
Abbreviations: SIT: simply ignore treatment (in SIT1 predictor X2 is considered unobserved; in 
SIT2 both predictors X1 and X2 are considered observed); AUT: analysis of untreated individuals 
(in AUT1 predictor X2 is considered unobserved; in AUT2 both predictors X1 and X2 are 
considered observed); IPW: inverse probability weighting (in IPW1 predictor X2 is considered 
unobserved; in IPW2 both predictors X1 and X2 are considered observed); MT: model includes 
treatment (in MT1 predictor X2 is considered unobserved; in MT2 both predictors X1 and X2 are 
considered observed). The O:E ratio is the ratio of the mean observed risk of the outcome and the 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
7 
 
mean predicted risk of the outcome. Ratios are average over 1000 simulations. Standard errors 
are the average standard error of the association between the predictor X1 and the outcome, 
averaged over 1000 simulations. 
Note that the method in which treatment as well as the predictors X1 and X2 are explicitly 
modelled performs even better than the reference (which is based on the data generating model), 
because chance processes are also accounted for in the analytical method.  
 
